Business Update
Genmab licenses MIF receptor target from Cytokine PharmaSciences
Published in Gene Therapy Weekly, December 21st, 2006
Genmab intends to develop therapeutic human antibodies to the licensed target. Details of the agreement were not disclosed.
"We are enthusiastic about this target, especially as there has been positive proof of concept data in experimental animal models," said Lisa N. Drakeman, PhD, chief executive officer of Genmab.
Denny Willson, president and CEO of Cytokine PharmaSciences, stated, "Genmab is a world-class company in the area of developing human antibody therapeutics. We are pleased to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-12-21)
More Articles from Gene Therapy Weekly
- Cardiovascular Research
Scientists work to identify genes that contribute to early heart attack risk - Neurology
First international gene screen for typical ALS is on track - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at University of Washington, Department of Medicine - Cancer Gene Therapy
Research from Third Military Medical University, Institute of Gastroenterology in cancer gene therapy provides new insights - Cancer Gene Therapy
Research on cancer gene therapy discussed by scientists at University of Zurich, Department of Biochemistry - Cancer Gene Therapy
Researchers from Soochow University, Department of Urology describe findings in cancer gene therapy - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
